Panacea Index Logo

Command Palette

Search for a command to run...

Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

International journal of molecular sciences
January 1, 1970
Mark F McCarty et al. (3 authors)
Journal ArticleReviewHuman StudyAnimal Study
Study Details

Study Goal

The researchers aimed to evaluate the potential of N-Acetylcysteine, among other nutraceuticals, to aid in preserving bone mass by addressing key signaling pathways involved in bone health.

Results Summary

The study suggests that N-Acetylcysteine, when combined with other nutraceuticals and minerals, may help preserve bone health, though specific results for N-Acetylcysteine alone are not detailed. Many of these agents, including N-Acetylcysteine, have shown favorable effects on bone density in rodent models.

Population

Rodent models of bone loss (specific human population not mentioned).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (18)
InterventionDirectionEndpointPopulationDosageImpactClaim #
ferulic acid
increase
Sirt1 activation
-
-
can be promoted
#1
N1-methylnicotinamide
increase
Sirt1 activation
-
-
can be promoted
#2
melatonin
increase
Sirt1 activation
-
-
can be promoted
#3
nicotinamide riboside
increase
Sirt1 activation
-
-
can be promoted
#4
glucosamine
increase
Sirt1 activation
-
-
can be promoted
#5
thymoquinone
increase
Sirt1 activation
-
-
can be promoted
#6
berberine
increase
AMPK
-
-
is a clinically useful activator
#7
metformin
increase
AMPK
-
-
is a clinically useful activator
#8
lipoic acid
increase
Nrf2 activity
-
-
can promote
#9
melatonin
increase
Nrf2 activity
-
-
can promote
#10
thymoquinone
increase
Nrf2 activity
-
-
can promote
#11
astaxanthin
increase
Nrf2 activity
-
-
can promote
#12
crucifera-derived sulforaphane
increase
Nrf2 activity
-
-
can promote
#13
pharmacological doses of biotin
increase
soluble guanylate cyclase (sGC)
-
-
can directly stimulate
#14
certain flavonols, notably quercetin
decrease
CK2
-
high nanomolar concentrations that may be clinically relevant
can inhibit
#15
Many, though not all, of these agents
increase
bone density and structure
rodent models of bone loss
-
have shown favorable effects
#16
Complex nutraceutical regimens providing a selection of these nutraceuticals in clinically meaningful doses
increase
bone health
-
-
may have an important potential for preserving
#17
Concurrent supplementation with taurine, N-acetylcysteine, vitamins D and K2, and minerals, including magnesium, zinc, and manganese, plus a diet naturally high in potassium
increase
preserving bone health
-
-
may also be helpful
#18
Abstract

There is a vast pre-clinical literature suggesting that certain nutraceuticals have the potential to aid the preservation of bone mass in the context of estrogen withdrawal, glucocorticoid treatment, chronic inflammation, or aging. In an effort to bring some logical clarity to these findings, the signaling pathways regulating osteoblast, osteocyte, and osteoclast induction, activity, and survival are briefly reviewed in the present study. The focus is placed on the following factors: the mechanisms that induce and activate the RUNX2 transcription factor, a key driver of osteoblast differentiation and function; the promotion of autophagy and prevention of apoptosis in osteoblasts/osteoclasts; and the induction and activation of NFATc1, which promotes the expression of many proteins required for osteoclast-mediated osteolysis. This analysis suggests that the activation of sirtuin 1 (Sirt1), AMP-activated protein kinase (AMPK), the Nrf2 transcription factor, and soluble guanylate cyclase (sGC) can be expected to aid the maintenance of bone mass, whereas the inhibition of the serine kinase CK2 should also be protective in this regard. Fortuitously, nutraceuticals are available to address each of these targets. Sirt1 activation can be promoted with ferulic acid, N1-methylnicotinamide, melatonin, nicotinamide riboside, glucosamine, and thymoquinone. Berberine, such as the drug metformin, is a clinically useful activator of AMPK. Many agents, including lipoic acid, melatonin, thymoquinone, astaxanthin, and crucifera-derived sulforaphane, can promote Nrf2 activity. Pharmacological doses of biotin can directly stimulate sGC. Additionally, certain flavonols, notably quercetin, can inhibit CK2 in high nanomolar concentrations that may be clinically relevant. Many, though not all, of these agents have shown favorable effects on bone density and structure in rodent models of bone loss. Complex nutraceutical regimens providing a selection of these nutraceuticals in clinically meaningful doses may have an important potential for preserving bone health. Concurrent supplementation with taurine, N-acetylcysteine, vitamins D and K2, and minerals, including magnesium, zinc, and manganese, plus a diet naturally high in potassium, may also be helpful in this regard.

Medical Subject Headings (MeSH)
AMP-Activated Protein KinasesBone DensityCell DifferentiationDietary SupplementsMelatoninNF-E2-Related Factor 2OsteoblastsOsteoclastsSirtuin 1Soluble Guanylyl CyclaseHumansAnimals
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality60/10
Citation Metrics
Total Citations15
Citations/Year5.0
Relative Citation Ratio1.88
NIH Percentile72.6%
Research Impact Scores
APT Score0.05
Weight Score0.72
Normalized Score0.60
Related Supplements